Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Recurrent Laryngeal Squamous Cell Carcinoma: early-phase trial registry

4 of 10 indexed Recurrent Laryngeal Squamous Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

10 US clinical trials · 4 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Recurrent Laryngeal Squamous Cell Carcinoma: 10 US clinical trials tracked, 4 recruiting.

Recurrent Laryngeal Squamous Cell Carcinoma is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 6 of these trials.

Enrollment posture brief

Registry condition recurrent-laryngeal-squamous-cell-carcinoma

OPEN 4 | RECR 40% | LATE 2 | EARLY 8 | RANK #1724 | SPON 6

Volume-matched condition peers

Nearest open-share peer: Acute Myeloid Leukemia (AML) (40% recruiting · 30 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Recurrent Laryngeal Squa (th…40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Recurrent Laryngeal Squamous Cell Carcinoma

Recurrent Laryngeal Squamous Cell Carcinoma lists 4 open slots (40% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Recurrent Laryngeal Squamous Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Recurrent Laryngeal Squamous Cell Carcinoma is recruiting below its size-band peers.

    4 of 10 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Recurrent Laryngeal Squamous Cell Carcinoma research.

    National Cancer Institute (NCI) accounts for 6 of 10 trials (60%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Recurrent Laryngeal Squamous Cell Carcinoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 48 among the 10 trials that report a genuine target (sentinel values excluded). 7 of those (70%) plan for fewer than 100 participants.

  4. Recurrent Laryngeal Squamous Cell Carcinoma research is mostly interventional.

    10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 26Phase 32

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2 188 participants

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

NCT04671667
RECRUITING Phase 3 158 participants

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

National Cancer Institute (NCI)

NCT06589804
RECRUITING Phase 1 45 participants

Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

Ohio State University Comprehensive Cancer Center

NCT04754321
RECRUITING Phase 2 44 participants

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

NCT06980038
ACTIVE NOT RECRUITING Phase 3 403 participants

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

NCT00588770
ACTIVE NOT RECRUITING Phase 2 52 participants

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

National Cancer Institute (NCI)

NCT05172258
ACTIVE NOT RECRUITING Phase 2 48 participants

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

M.D. Anderson Cancer Center

NCT00494182
ACTIVE NOT RECRUITING Phase 2 46 participants

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Marcelo Bonomi

NCT04862650
ACTIVE NOT RECRUITING Phase 2 36 participants

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Emory University

NCT03468218
ACTIVE NOT RECRUITING Phase 1 7 participants

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

NCT04576091

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 6
Phase 3 2

Top Sponsors

National Cancer Institute (NCI) 6 trials
Marcelo Bonomi 1 trials
Emory University 1 trials
Ohio State University Comprehensive Cancer Center 1 trials
M.D. Anderson Cancer Center 1 trials

Named interventions

Most-linked intervention names on Recurrent Laryngeal Squamous Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Computed Tomography Procedure
5 trials
Pembrolizumab Biological
5 trials
Biospecimen Collection Procedure
4 trials
Carboplatin Drug
4 trials
Cemiplimab Biological
2 trials
Paclitaxel Drug
2 trials
Biopsy Procedure Procedure
2 trials
Magnetic Resonance Imaging Procedure
2 trials

US sites by state

Facility locations filed on Recurrent Laryngeal Squamous Cell Carcinoma trials. A trial with sites in several states counts in each.

California 6 trials
Illinois 3 trials
Florida 3 trials
Arkansas 3 trials
Texas 2 trials
Ohio 2 trials
New York 2 trials
District of Columbia 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Recurrent Laryngeal Squamous Cell Carcinoma page

10 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 Recurrent Laryngeal Squamous Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • National Cancer Institute (NCI) sponsors the most Recurrent Laryngeal Squamous Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Laryngeal Squamous Cell Carcinoma condition card totals 10 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.